Compare CRVL & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRVL | XENE |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.4B |
| IPO Year | 1991 | 2014 |
| Metric | CRVL | XENE |
|---|---|---|
| Price | $70.02 | $43.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $53.91 |
| AVG Volume (30 Days) | 177.8K | ★ 793.2K |
| Earning Date | 02-03-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.11 | N/A |
| EPS | ★ 2.02 | N/A |
| Revenue | ★ $933,841,000.00 | $7,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.62 | ★ N/A |
| Revenue Growth | ★ 10.43 | N/A |
| 52 Week Low | $66.49 | $26.74 |
| 52 Week High | $128.61 | $46.60 |
| Indicator | CRVL | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 54.58 |
| Support Level | $69.41 | $42.89 |
| Resistance Level | $71.30 | $44.57 |
| Average True Range (ATR) | 1.92 | 1.34 |
| MACD | 0.07 | -0.12 |
| Stochastic Oscillator | 45.52 | 25.32 |
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.